ADC Therapeutics
ADCT
55 hedge funds and large institutions have $683M invested in ADC Therapeutics in 2021 Q4 according to their latest regulatory filings, with 11 funds opening new positions, 14 increasing their positions, 15 reducing their positions, and 9 closing their positions.
88% more call options, than puts
Call options by funds: $2.04M | Put options by funds: $1.09M
22% more first-time investments, than exits
New positions opened: 11 | Existing positions closed: 9
4% more funds holding
Funds holding: 53 → 55 (+2)
1.31% more ownership
Funds ownership: 42.74% → 44.05% (+1.3%)
7% less repeat investments, than reductions
Existing positions increased: 14 | Existing positions reduced: 15
23% less capital invested
Capital invested by funds: $891M → $683M (-$208M)
25% less funds holding in top 10
Funds holding in top 10: 4 → 3 (-1)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
EAM
Eventide Asset Management
Boston,
Massachusetts
|
+$16M |
| 2 |
PAMS
Pictet Asset Management (Switzerland)
Geneva 73,
Switzerland
|
+$4.56M |
| 3 |
AllianceBernstein
Nashville,
Tennessee
|
+$3.7M |
| 4 |
Bank of America
Charlotte,
North Carolina
|
+$2.23M |
| 5 |
ERSOT
Employees Retirement System of Texas
Austin,
Texas
|
+$1.16M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
B
Bailard
Foster City,
California
|
-$1.96M |
| 2 |
RG
Redmile Group
San Francisco,
California
|
-$1.89M |
| 3 |
JP Morgan Chase
New York
|
-$1.76M |
| 4 |
Voloridge Investment Management
Jupiter,
Florida
|
-$838K |
| 5 |
Man Group
London,
United Kingdom
|
-$538K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
TFA
51
Toth Financial Advisory
Leesburg,
Virginia
| $1K | – | – | – |
|
52
Citigroup
New York
| $1K | +$772 | +32 | New |
|
53
Simplex Trading
Chicago,
Illinois
| $1K | +$2.15K | +89 | New |
|
|
B
54
Bailard
Foster City,
California
| – | -$1.96M | -72,000 | Closed |
|
|
55
Voloridge Investment Management
Jupiter,
Florida
| – | -$838K | -30,847 | Closed |
|
|
56
Man Group
London,
United Kingdom
| – | -$538K | -19,813 | Closed |
|
57
Citadel Advisors
Miami,
Florida
| – | -$467K | -19,346 | Closed |
|
|
SCA
58
Snowden Capital Advisors
New York
| – | -$389K | -14,323 | Closed |
|
|
CSS
59
Cubist Systematic Strategies
Stamford,
Connecticut
| – | -$251K | -9,256 | Closed |
|
60
Deutsche Bank
Frankfurt Am Main Ge,
Germany
| – | -$8K | -300 | Closed |
|
|
RE
61
RBC Europe
London,
United Kingdom
| – | -$3.12K | -115 | Closed |
|
ADCT Hedge Fund Activity: Q4 2021 in Review
55 of the 6,498 institutional investors tracked by Wall St. Rank reported a position in ADC Therapeutics (ADCT) for Q4 2021, worth a combined $683M — down 23% from $891M a quarter earlier.
Buyers outnumbered sellers: 11 funds opened new ADCT positions and 9 closed out — a net gain of 2 holders — while 14 added to existing stakes and 15 trimmed.
The largest buyer was Eventide Asset Management, adding an estimated $16M. The largest seller was Bailard, exiting entirely with an estimated $1.96M sold.
- 55 institutional investors held ADC Therapeutics (ADCT) as of Q4 2021, up from 53 in Q3 2021.
- Funds reported $683M of ADC Therapeutics stock for Q4 2021, down 23% quarter-over-quarter.
- 11 funds opened new ADC Therapeutics positions in Q4 2021 and 9 closed out, a net change of +2 holders.
- The largest ADC Therapeutics buyer in Q4 2021 was Eventide Asset Management, an estimated $16M added.
- The largest ADC Therapeutics seller in Q4 2021 was Bailard, an estimated $1.96M sold.
Based on aggregated 13F filings for Q4 2021.